Clinical Trials

Ivonescimab is being investigated in phase 3 clinical trial against the combination of tislelizumab and chemotherapy.

Fadraciclib, a highly selective inhibitor of CDK2 and CDK9, is being investigated in clinical trials for patients with solid tumors and hematologic malignancies.

A number of trials evaluating rintatolimod as a combinational therapy for a wide range of solid tumor types are underway and planned, including in pancreatic and breast cancer.

After success, preclinically and in a phase 1 dose-finding study, the phase 2 study of BDC-1001 has begun.

For the first time ever, patients with relapsed or refractory B-cell non-Hodgkin lymphoma can receive the experimental chimeric antigen receptor T-cell therapy, CLN-978, in a clinical trial.

Determining the safety and efficacy of zipalertinib combined with chemotherapy for patients with EGFR exon 20 insertion mutation-positive non–small cell lung cancer are the key goals of the newly-launched phase 3 REZILIENT3 study.

The phase 1 study is evaluating the combination of a CD19-targeting chimeric antigen receptor and an orthogonal IL-2 in patients with CD19-positive hematologic malignancies.

Treatment has been initiated in a phase 1/2 study of TNG260 added to pembrolizumab in patients with advanced or metastatic solid tumors.

Investigators are evaluating the efficacy and safety of selinexor vs placebo when used as a maintenance therapy for patients with p53 wild-type advanced or recurrent endometrial cancer.

In an interview with Targeted Oncology, Lucia Masarova, MD, discussed the ongoing EXCEED-ET clinical trial and its potential to provide a new option to alter disease and ward off post-essential thrombocytopenia myelofibrosis in adult patients.

Following early efficacy demonstrated with DKN-01, bevacizumab, and chemotherapy in part A of the DeFianCe study, part B has begun enrolling patients with advanced colorectal cancer.

An investigation of selective targeting of A2AR in patients with certain solid tumors is underway in a first-in-human study.

In season 4, episode 9 of Targeted Talks, Kerry Reynolds, MD, discusses the occurrence of myocarditis in patients with cancer treated with immune checkpoint inhibitors.

Treatment with the investigational drug FHD-286 exhibits positive results in patients with metastatic uveal melanoma and will be explored further in acute myeloid leukemia and myelodysplastic syndrome.

A phase 1 study is assessing the safety and tolerability of briquilimab in patients with lower-risk myelodysplastic syndrome.

E-602 represents the first glyco-immune checkpoint inhibitor and the early safety as well as translational immunology associated with the treatment in patients with advanced cancer is promising, according to Jason Luke, MD, FACP.

According to the developer of TTI-101, the REVERT-Liver Cancer trial is the second of three phase 2 trials involving the agent.

The safety and efficacy of the combination of lifileucel and pembrolizumab is being assessed in the phase 3 TILVANCE-301 among patients with untreated, unresectable, or metastatic melanoma.

Although dosing will continue in iMMagine-1 for patients who responded well to CART-ddBCMA, recruitment has been halted due to to a safety concern.

The FDA is no longer concerned about the safety of MT-0169, and the developer of the agent plans to focus its effort on the extramedullary myeloma population.

ACTION-1 is investigating RYZ101 versus standard-of-care therapy in patients with SSTR-positive gastroenteropancreatic neuroendocrine tumors after 177Lu-SSA therapy.

A phase 1 study is exploring gamma delta T-cell therapy for the first time in patients with relapsed or refractory B-cell malignancies.

The claudin 18.2 antibody-drug conjugate ATG-022 is being investigated in a phase 1 study as a potential treatment for advanced or metastatic solid tumors.

Development of PYX-201 in advanced solid tumors is underway, and the drug has grabbed the FDA's attend with a phase 1 study in pancreatic cancer.

This trial of HST-1011 will evaluate the safety, tolerability, pharmacokinetics, harmacodynamics, and preliminary clinical activity of the agent when administered as a monotherapy or in combination with cemiplimab.

According to Alice P. Chen, MD, the phase 2 study of atezolizumab alone or atezolizumab plus bevacizumab has a unique design.

A patient treated with the second highest dose level of FHD-609 had a grade 4 adverse event. Enrollment in the study of the agent in patients with synovial sarcoma or SMARCB-1 deleted tumors has been halted.

The FDA continues to push forward PSMA-targeted therapies to address unmet needs for patients with metastatic castration-resistant prostate cancer.